EP3718130A1 - Adhesion layer bonded to an activated surface - Google Patents
Adhesion layer bonded to an activated surfaceInfo
- Publication number
- EP3718130A1 EP3718130A1 EP18883168.9A EP18883168A EP3718130A1 EP 3718130 A1 EP3718130 A1 EP 3718130A1 EP 18883168 A EP18883168 A EP 18883168A EP 3718130 A1 EP3718130 A1 EP 3718130A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- group
- construct
- inorganic
- adhesion layer
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/04—Metals or alloys
- A61L27/042—Iron or iron alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/0077—Special surfaces of prostheses, e.g. for improving ingrowth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/04—Metals or alloys
- A61L27/047—Other specific metals or alloys not covered by A61L27/042 - A61L27/045 or A61L27/06
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/04—Metals or alloys
- A61L27/06—Titanium or titanium alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/30—Inorganic materials
- A61L27/306—Other specific inorganic materials not covered by A61L27/303 - A61L27/32
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3633—Extracellular matrix [ECM]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D3/00—Pretreatment of surfaces to which liquids or other fluent materials are to be applied; After-treatment of applied coatings, e.g. intermediate treating of an applied coating preparatory to subsequent applications of liquids or other fluent materials
- B05D3/10—Pretreatment of surfaces to which liquids or other fluent materials are to be applied; After-treatment of applied coatings, e.g. intermediate treating of an applied coating preparatory to subsequent applications of liquids or other fluent materials by other chemical means
- B05D3/101—Pretreatment of polymeric substrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/0077—Special surfaces of prostheses, e.g. for improving ingrowth
- A61F2002/0081—Special surfaces of prostheses, e.g. for improving ingrowth directly machined on the prosthetic surface, e.g. holes, grooves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/0077—Special surfaces of prostheses, e.g. for improving ingrowth
- A61F2002/0086—Special surfaces of prostheses, e.g. for improving ingrowth for preferentially controlling or promoting the growth of specific types of cells or tissues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/18—Modification of implant surfaces in order to improve biocompatibility, cell growth, fixation of biomolecules, e.g. plasma treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/02—Methods for coating medical devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/06—Coatings containing a mixture of two or more compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/08—Coatings comprising two or more layers
Definitions
- the present invention is related to the field of activation of otherwise unreactive surfaces to make them susceptible to the chemical bonding of coatings, where the coatings allow modification of surface properties.
- Such coated surfaces have utility as scaffolds for cell growth, reconstructive medicine, and medical devices.
- ECM extracellular matrix
- a goal of regenerative medicine is to promote formation of new tissue that closely resembles the normal tissue in organization and function. Controlling cell growth in a spatially defined way enables regeneration of damaged or diseased tissues having the proper alignment of constituent cells and/or alignment of molecular complexes that the cells produce.
- cells direct the arrangement of ECM fibrils to correspond to their actin filaments by using cell surface receptors that are indirectly connected to the actin cytoskeleton. Therefore, a major challenge in regenerative medicine is to promote cells to assemble ECM fibrils, such as collagen, into particular orientations or alignments on a scaffold device in order to generate tissues with the required functional properties.
- Such a scaffold requires an appropriate substrate surface on which to attach cells in an environment that stimulates the generation of an ECM.
- the term“covalent” bond refers to a chemical bond that involves the sharing of electron pairs between atoms.
- the term“coordinate”,“coordinative” or “coordinate covalent” bond denotes a two-center, two-electron covalent bond in which both electrons derive from the same atom, such as the bonding of metal ions to ligands.
- “ionic” bonding involves electrostatic attraction between oppositely charged ions, where electrons are not shared, but one or more electrons are localized on one of the atoms (the anion) and removed from the other atom (the cation).
- bonded means affixed or attached, preferably chemically attached without the use of an adhesive.
- the chemical bond is preferably a covalent or coordinative attachment.
- the terms“reactive”, and“unreactive” refer to the ability of a specific functional group to chemically bond with other functional groups, for example in an inorganic adhesion layer.
- “about” generally includes up to plus or minus 10% of the indicated number.
- “about 10%” may indicate a range of 9% to 11%
- “about 20” may mean from 18 to 22.
- Preferably“about” includes up to plus or minus 6% of the indicated value.
- “about” includes up to plus or minus 5% of the indicated value. Other meanings of“about” may be apparent from the context, such as rounding off, so, for example “about 1” may also mean from 0.5 to 1.4.
- an appropriate substrate surface on which to attach cells in an environment that stimulates the generation of an ECM comprises a polymer, metal or metalloid surface having appropriate surface functional groups, with or without a chemically bonded inorganic oxide adhesion layer.
- a self- assembled monolayer (SAM) of appropriate ligands either chemically bonded directly to the surface functional groups (without the interposition of an inorganic oxide adhesion layer), or chemically bonded to the attached inorganic oxide adhesion layer.
- SAM self- assembled monolayer
- These ligands can have surface-modifying properties, and can also support the attachment of cells, providing a suitable environment for generation of an ECM.
- polymers there are broad classes of polymers, metals and other materials that do not have exposed surface functional groups in sufficient density or sufficient reactivity to form covalent or coordinative bonds with the precursor inorganic alkoxides of the bonded adhesion layers. These classes include various polymer, metal and metalloid surfaces.
- polymers and other materials that are otherwise unreactive or of low reactivity toward the chemical bonding of coatings can be activated through oxidation or amination methods, including chemical oxidation using chemical oxidants. Other methods include oxygen or nitrogen plasma discharge and corona discharge. These chemical reagents and methods are able to generate hydroxyl, oxy, oxo, carbonyl, carboxylic acid or carboxylate functional groups on the surface, or, in the case of nitrogen plasma, amino groups. Such functional groups can then react with an inorganic alkoxide (such as a Zr alkoxide or Ti alkoxide) to form a chemically bound inorganic adhesion layer.
- an inorganic alkoxide such as a Zr alkoxide or Ti alkoxide
- Suitable polymers that do not react readily with an inorganic alkoxide to form an adhesion layer include polyalkanes or other polymers such as polysiloxanes, polyalkylarenes, polyolefins, polythiols, and polyphosphines.
- One aspect of the invention is directed to a construct comprising a coated activated surface comprising an inorganic oxide adhesion layer chemically bonded to the surface, where the inorganic oxide is selected from the group consisting of the oxides of Ti, Zr, Al, Mg, Si, Zn, Mo, Nb, Ta, Sn, W, and V.
- the inorganic adhesion layer of the construct is selected from the group consisting of the oxides of Al, Ti, Zr, Si, Mg and Zn.
- the polymers can be selected from polysiloxanes (such as polydimethylsiloxane (PDMS)), polyalkanes, polyalkylarenes, polyaldehydes, polyolefins, polythiols, and polyphosphines.
- the activated surface coated with an inorganic oxide can further comprise a self- assembled monolayer (SAM) bonded to the adhesion layer, where the SAM is selected from organic compounds comprising a phosphonic, carboxylic, sulfonic, phosphinic, phosphoric, sulfinic, or hydroxamic group.
- the SAM comprises a self-assembled monolayer of phosphonates (SAMP).
- the phosphonates can be selected from the group consisting of hydrophobic phosphonates, cell-adhesive phosphonates and phosphonates capable of further metal-catalyzed coupling.
- the phosphonates can be selected from the group consisting of phosphonic acids of structure
- R group is selected from the group consisting of optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted alkenyl, optionally substituted heteroalkenyl, optionally substituted alkynyl, optionally substituted heteroalkynyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, and optionally substituted hetero arylalkyl, where heteroalkyl, heteroalkenyl, heteroalkynyl, heteroaryl and hetero arylalkyl contain one or more heteroatoms selected from the group consisting of O, N and S.
- Another aspect of the invention is directed to a construct for medical use comprising the inorganic oxide-coated activated surface further containing a SAM or SAMP bonded to the inorganic oxide coating.
- This construct can further comprise other useful moieties covalently bound to the SAM or SAMP, such as alkyne or azide groups which allow further elaboration using the so-called“click” reaction, electrochemically active moieties, photochemically active moieties, cell- attractive moieties, cell-adhesive moieties, or anti- infective moieties.
- this medical construct can further comprise cells attached to the SAM- or SAMP-coated surface.
- the cells are can be selected from the group consisting of fibroblasts, endothelial cells, keratinocytes, osteoblasts, chondroblasts, chondrocytes, hepatocytes, macrophages, cardiac muscle cells, smooth muscle cells, skeletal muscle cells, tendon cells, ligament cells, epithelial cells, stem cells, neural cells, PC12 cells, neural support cells, Schwann cells, radial glial cells, cells that form neurospheres, neural tumor cells, glioblastoma cells and neuroblastoma cells.
- the fibroblasts can comprise NIH 3T3 fibroblasts.
- the construct can further comprise an extracellular matrix (ECM). The construct can be further decelluarized, leaving the ECM attached.
- ECM extracellular matrix
- the method can further comprise: d) removing the coated substrate from the coating solution; and e) rinsing with a solvent to provide a rinsed coated substrate.
- the method can still further comprise: f) heating the rinsed coated substrate to 35 to 40°C.
- steps b) and c) can be replaced by vapor deposition of an inorganic alkoxide onto the surface, providing the inorganic oxide adhesion layer.
- the inorganic compound of the method can be selected from the group consisting of the alkoxides of Al, Ti, Zr, Si, Mg and Zn.
- the alkoxide can be selected from the group consisting of methoxide, ethoxide, propoxide, iso-propoxide, butoxide, iso-butoxide, sec- butoxide, and tert-butoxide.
- Figure 1 shows the infrared (IR) spectrum of a representative oxygen plasma-oxidized polydimethylsiloxane (PDMS) construct having a titanium Ao-propoxide adhesion layer with an octadecylphosphonic acid (ODPA) self-assembled monolayer thereon (Example 1).
- PDMS oxygen plasma-oxidized polydimethylsiloxane
- Figure 2 displays the elemental composition pattern consistent with the native form of a heparin molecule on a stainless-steel surface (Example 5) as determined by X-ray photon spectroscopy analysis.
- the inventive method can be employed on polymer or metal surfaces that are otherwise unreactive with a reactive metal alkoxide.
- oxidation or amination of polymers and other materials such as phosphonates or siloxanes, that are otherwise unreactive toward bonding of coatings can be activated through oxidation methods including chemical oxidation using chemical oxidants such as permanganate, chlorite, chromic acid, chromate, other chromic acid derivatives, osmium tetroxide, ruthenium tetroxide, iodate, peracids, peroxides, Fenton’s reagent (hydrogen peroxide/Fe(II)), lead tetraacetate, lead
- chemical oxidants such as permanganate, chlorite, chromic acid, chromate, other chromic acid derivatives, osmium tetroxide, ruthenium tetroxide, iodate, peracids, peroxides, Fenton’s
- Oxygen plasma activation can be accomplished as described in US Patent Publication No. 2013/0005660 to Dong et al., or as described in US Patent 9,655,992 to Clevenger et al., both of which are incorporated herein by reference in their entirety.
- Such functional groups can then react with an inorganic alkoxide (such as a Zr alkoxide or Ti alkoxide) to form a chemically bonded inorganic adhesion layer.
- Suitable unreactive polymers are unreactive by virtue of lacking appropriate reactive functional groups on the polymer surface, such as the aforesaid hydroxyl, oxy, oxo, carbonyl, carboxylic acid or carboxylate functional groups.
- Suitable unactivated polymers include:
- polyalkanes or other polymers with terminal alkyl groups such as polysiloxanes, where C-H bond oxidation would yield C-OH or COOH groups (alcohols or acids) that are reactive;
- the unreactive metal surfaces are those which are terminated with metallic oxides where the metal oxides themselves are not suitably reactive, such as the native oxide layer on titanium (titanium dioxide) or the native oxide layer on silicon (silicon dioxide).
- Other metals in this category would include chromium, and alloys of titanium or chromium, including stainless steel and cobalt chrome.
- Suitable metalloids for use with the inventive method include Si, GaAs, GaP, GaN, A1N and perovskites, where oxidation would introduce surface -OH or bridging oxy groups.
- silicon dioxide and silicon hydride-terminated silicon are suitable for activation using the present methods.
- Such activated surfaces provide a platform or substrate on which to construct a chemically bonded adhesion layer which can then be used to attach a self- assembled monolayer (SAM), such as a self-assembled monolayer of a phosphonate (SAMP), that would control the surface properties of the material, for example to make it more, or less, hydrophobic, or to attach other useful moieties such as alkyne or azide groups (reactive for “click” chemical coupling), electrochemically active moieties, photochemically active moieties, cell- attractive moieties, cell-adhesive moieties, or anti-infective moieties.
- SAM self- assembled monolayer
- SAMP phosphonate
- Suitable anti-infective moieties are disclosed in the following references, incorporated herein by reference in their entireties: US Patent Publication No. 2010/0215643 to Clevenger et a , US Patent Publication No. 2013/0005660 to Dong et ak, and US Patent 9,655,992 to Clevenger et ak
- the surface of the substrate comprising a SAM can be patterned or unpatterned.
- the non-oxygen inorganic species preferably has low toxicity in medical applications, and can be advantageously selected from the group consisting of Ti, Zr, Al, Mg, Si, Zn, Mo, Nb, Ta, Sn, W, and V.
- the inorganic species is Al, Ti, Zr, Si, Mg or Zn. More preferably the inorganic species is Al, Si, Ti or Zr.
- the inorganic species can be Ak
- the inorganic species can be Ti.
- the inorganic species can be Zr.
- the inorganic species can be Mg.
- the inorganic species can be Si.
- the inorganic species can be Zn.
- the inorganic species can be Mo.
- the inorganic species can be Nb.
- the inorganic species can be Ta.
- the inorganic species can be Sn.
- the inorganic species can be W.
- the inorganic species can be V.
- the adhesion layer comprises reactive alkoxides on the surface, which can react with appropriate organic compounds to form a SAM or SAMP, but can also react with other organic moieties of interest to chemically bond them directly to the adhesion layer, without the intervention of a SAM or SAMP.
- the adhesion layer-coated surface can further comprise a self-assembled monolayer (SAM) bonded to the adhesion layer, where the SAM is selected from organic compounds comprising a phosphonic, carboxylic, sulfonic, phosphinic, phosphoric, sulfinic, or hydroxamic group.
- SAM comprises a self-assembled monolayer of phosphonates (SAMP).
- the phosphonates can be selected from hydrophobic phosphonates, cell-adhesive phosphonates and phosphonates capable of further metal-catalyzed coupling.
- Suitable phosphonates can be selected from the group consisting of phosphonic acids having the structure:
- R group is selected from the group consisting of optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted alkenyl, optionally substituted heteroalkenyl, optionally substituted alkynyl, optionally substituted heteroalkynyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, and optionally substituted hetero arylalkyl, where heteroalkyl, heteroalkenyl, heteroalkynyl, heteroaryl and hetero arylalkyl contain one or more heteroatoms selected from the group consisting of O, N and S.
- the optional substitution on the R group can comprise one or more groups selected from polyol moieties, sugar alcohol moieties, hydroxyl functional groups, amino functional groups, carboxylic acid functional groups, carboxylate ester functional groups, phosphonic acid functional groups, phosphonate functional groups, ether functional groups, alkyne functional groups, azide functional groups and thiol functional groups.
- the alkyl group can be a C 5 -C 24 alkyl, or a C 6 -C 20 alkyl, or a Cx to Ci 8 alkyl.
- the alkyl group can be a C3, C 4 , Ce, Cx, C10, C12, Ci 4 , Ci6, Cix, or C20 alkyl group.
- the alkyl group can be a C 4 -C 24 alkyl, or a Ce- C20 alkyl, or a Cs to Ci 8 alkyl.
- the alkyl group can be a C3, C4, C 6 , C 8 , C10, C12, C14, Ci6, Ci 8 , or C 20 alkyl group.
- the cell-adhesive phosphonates are selected from the group consisting of C 3 -C 30 a,w-diphosphonates.
- the alkylene group can be a C 3 , C 4 , Ce, C 8 , C10, C12, C14, Ci6, Ci8, C20, C22, C24, C26, C28, or C30 alkylene group.
- the a,w-diphosphonic acid can be a C 3-16 diphosphonic acid, preferably a C 4-12 diphosphonic acid, more preferably a C 4, or a Ce, or a Cs, or a C10, or a C12 diphosphonic acid.
- a,w-diphosphonic acid can be 1,4-butanediphosphonic acid, or 1,6-hexanediphosphonic acid, or 1,8-octanediphosphonic acid, or 1,10-decanediphosphonic acid, or 1,12- dodecanediphosphonic acid, or mixtures of two or more thereof.
- the phosphonates are alkynes, most preferably terminal alkynes.
- the alkynyl group can be a C 5 -C 24 alkynyl, or a C 6 -C 20 alkynyl, or a Cs to Cis alkynyl.
- the alkynyl group can be a C 3 , C 4 , Ce, C 8 , Cio, Ci 2 , Ci 4 , Ci6, Ci 8 , or C20 alkynyl group.
- the alkynyl group bears a terminal alkyne.
- the SAMP of the coated construct comprises a phosphonic acid covalently attached to the inorganic oxide adhesion layer, which phosphonic acid contains functionality adapted for cell binding.
- the cell-binding phosphonic acid can comprise one or more functional groups selected from polyol moieties, sugar alcohol moieties, hydroxyl functional groups, amino functional groups, carboxylic acid functional groups, carboxylate ester functional groups, phosphonic acid functional groups, phosphonate functional groups, ether functional groups, alkyne functional groups, azide functional groups and thiol functional groups.
- the phosphonic acid is a diphosphonic acid, more preferably an a,w-diphosphonic acid as described above.
- Example 3 describes a copper-catalyzed click coupling of a PDMS/adhesion layer/SAMP of phosphonodec-9-yne with phenyl azide to form a SAMP of terminated with a phenyltriazole.
- Click chemistry employs the cycloaddition reaction between a 1,3-dipole and a dipolarophile (specifically azide and alkyne), to form a five-membered ring.
- the azide and alkyne functional moieties are largely inert toward biological molecules and aqueous environments.
- the triazole has similarities to the ubiquitous amide moiety found in nature, but unlike an amide, it is not susceptible to cleavage. Additionally, triazoles are not readily oxidized or reduced. Reports and procedures on cycloaddition reactions between a 1,3 -dipole and a dipolarophile are readily available to one of ordinary skill in the art.
- alkyne groups can participate in various metal-catalyzed coupling reactions, such as palladium-catalyzed coupling reactions, to introduce additional functionality on a SAM or SAMP. Reactions such as the Sonogashira reaction are applicable.
- Example 2 describes the copper/palladium-catalyzed coupling of a PDMS/adhesion layer/SAMP of phosphonodec-9-yne with bromobenzene to form a SAMP of 10-phenylphosphonodec-9-yne.
- these moieties can include electrochemically active moieties, photochemically active moieties, cell- attractive moieties, cell-adhesive moieties, anti- infective moieties or antithrombogenic moieties, as disclosed herein.
- Example 4 describes PDMS coated with an adhesion layer formed from zirconium n-butoxide which can be directly reacted with glycerol, in the absence of a SAM or SAMP.
- Another aspect of the invention is directed to a construct for medical applications comprising the coated surface containing a SAM or SAMP bonded to the inorganic oxide coating.
- the construct can further comprise cells attached to the SAM- or SAMP-coated surface of the construct.
- the cells can be selected from the group consisting of fibroblasts, endothelial cells, keratinocytes, osteoblasts, chondroblasts, chondrocytes, hepatocytes, macrophages, cardiac muscle cells, smooth muscle cells, skeletal muscle cells, tendon cells, ligament cells, epithelial cells, stem cells, neural cells, PC12 cells, neural support cells, Schwann cells, radial glial cells, cells that form neurospheres, neural tumor cells, glioblastoma cells and neuroblastoma cells.
- the fibroblasts preferably comprise NIH 3T3 fibroblasts.
- the construct can further comprise an extracellular matrix (ECM).
- ECM is a collection of extracellular molecules secreted by cells that provides structural and biochemical support to the surrounding cells.
- the construct can be further decelluarized, leaving the ECM attached.
- the method can further comprise: d) removing the coated substrate from the coating solution; and e) rinsing with a solvent to provide a rinsed coated substrate.
- the method can still further comprise: f) heating the rinsed coated substrate to 35 to 40°C.
- steps b) and c) can be replaced by vapor phase deposition of an inorganic alkoxide onto the surface, providing the inorganic oxide adhesion layer.
- the inorganic compound of the method can be selected from the group consisting of the alkoxides of Al, Ti, Zr, Si, Mg and Zn.
- the alkoxide can be selected from the group consisting of methoxide, ethoxide, propoxide, iso-propoxide, butoxide, iso-butoxide, sec- butoxide, and tert-butoxide.
- the inorganic species is preferably not toxic in reconstructive medical applications, and can be advantageously selected from the group consisting of Ti, Zr, Al, Mg, Si, Zn, Mo, Nb, Ta, Sn, W, and V.
- the inorganic species is Al, Ti, Zr, Si, Mg or Zn. More preferably the inorganic species is Al, Si, Ti or Zr.
- the inorganic species can be Al.
- the inorganic species can be Ti.
- the inorganic species can be Zr.
- the inorganic species can be Mg.
- the inorganic species can be Si.
- the inorganic species can be Zn.
- the inorganic species can be Mo.
- the inorganic species can be Nb.
- the inorganic species can be Ta.
- the inorganic species can be Sn.
- the inorganic species can be W.
- the inorganic species can be V.
- Preferred alkoxides are selected from the group consisting of methoxide, ethoxide, propoxide, iso-propoxide, butoxide, iso-butoxide, sec- butoxide, and tert-butoxide.
- One aspect of the invention is directed to a construct comprising a) a surface activated to the chemical bonding of an inorganic adhesion layer that provides for further attachment of moieties that modify the overall surface properties, where the surface contains no accessible, sufficiently reactive functional groups on the surface, where activation comprises generation of reactive functional groups on the surface; and b) an inorganic adhesion layer chemically bonded to the activated surface via the reactive functional groups; where the functional groups are reactive with an inorganic alkoxide to form the inorganic adhesion layer.
- the surface of such a construct can comprise a polymer or a metal.
- the polymer can be selected from the group consisting of polyalkanes, polysiloxanes, polyalkylarenes, polyolefins, polythiols and polyphosphines.
- the metal can be selected of stainless steel and various alloys thereof.
- the surface functional groups of the construct are preferably selected from the group consisting of hydroxyl, oxy, oxo, carbonyl, carboxylic acid, carboxylate, and amino groups.
- the surface functional groups of the construct can be produced by chemical oxidation, using oxidizing agents such as permanganate, chlorite, chromic acid, chromate, osmium tetroxide, ruthenium tetroxide, iodate, peracids, peroxides, Fenton’s reagent, lead tetraacetate, lead tetraacetate/Mn(II), ozone, or oxygen.
- oxidizing agents such as permanganate, chlorite, chromic acid, chromate, osmium tetroxide, ruthenium tetroxide, iodate, peracids, peroxides, Fenton’s reagent, lead tetraacetate, lead tetraacetate/Mn(II), ozone, or oxygen.
- the surface functional groups can be generated using oxygen plasma discharge, nitrogen plasma discharge or corona discharge.
- the construct can further comprise a self-assembled monolayer (SAM) bonded to the inorganic adhesion layer, where the SAM is selected from organic compounds comprising a phosphonic, carboxylic, sulfonic, phosphinic, phosphoric, sulfinic, or hydroxamic group.
- SAM self-assembled monolayer
- the SAM can comprise a self-assembled monolayer of phosphonates (SAMP), where the phosphonates can be selected from the group consisting of hydrophobic phosphonates, cell- adhesive phosphonates and phosphonates capable of further metal-catalyzed coupling.
- SAMP self-assembled monolayer of phosphonates
- the phosphonates can be selected from the group consisting of hydrophobic phosphonates, cell- adhesive phosphonates and phosphonates capable of further metal-catalyzed coupling.
- the phosphonates can be selected from the group consisting of phosphonic acids of the structure
- R group is selected from the group consisting of optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted alkenyl, optionally substituted heteroalkenyl, optionally substituted alkynyl, optionally substituted heteroalkynyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, and optionally substituted hetero arylalkyl, where heteroalkyl, heteroalkenyl, heteroalkynyl, heteroaryl and hetero arylalkyl contain one or more heteroatoms selected from the group consisting of O, N and S.
- the cell-adhesive phosphonates can be selected from the group consisting of C 3 -C 30 a,w-diphosphonates.
- the construct can have a SAM or SAMP that further comprises an anti-infective agent covalently bound thereto.
- Suitable anti-infective agents include an antimicrobial selected from the group consisting of amikacin, gentamicin, kanamycin, neomycin, netilmicin, tobramycin, paromomycin, geldanamycin, herbimycin, loracarbef, ertapenem, doripenem, imipenem/cilastatin, meropenem, cefadroxil, cefazolin, cefalotin, cefalexin, cefaclor, cefamandole, cefoxitin, cefprozil, cefuroxime, cefditoren, cefoperazone, cefotaxime, cefpodoxime, ceftazidime, ceftibuten, ceftizoxime, ceftriaxone, cefepime, ceftaroline fosamil, ce
- trovafloxacin grepafloxacin, sparfloxacin, temafloxacin, mafenide, sulfonamidochrysoidine, sulfacetamide, sulfadiazine, silver, sulfadiazine, sulfamethizole, sulfamethoxazole, sulfanilimide, sulfasalazine, sulfisoxazole, trimethoprim, trimethoprim-sulfamethoxazole, demeclocycline, doxycycline, minocycline, oxytetracycline, tetracycline, clofazimine, dapsone, capreomycin, cycloserine, ethambutol, ethionamide, isoniazid, pyrazinamide, rifampicin, rifabutin, rifapentine, streptomycin, arsphenamine
- the anti- infective agent can be selected from the group consisting of chlorhexidine, biguanides, cationic ammonium compounds, pharmaceutically acceptable salts thereof, and mixtures of two or more thereof.
- the anti- infective agent can also be selected from the group consisting of cationic ammonium compounds, cationic ammonium dendrimers, silver, copper, cationic species and mixtures of two or more thereof.
- the cationic ammonium compounds can be selected from the group consisting of choline and choline derivatives.
- the anti-infective agent can comprise polysaccharides, chitosan, partially acetylated chitosan, polyglucosamine, chitosan diols, and other polyols (such as polyvinylalcohol) and aminoalcohols.
- Another aspect of the invention is directed to a method of forming an inventive construct comprising the steps of a) activating a surface to chemical bonding of an inorganic adhesion layer that provides for further attachment of moieties that modify the overall surface properties, wherein the surface contains no accessible, sufficiently reactive functional groups on the surface, the activating comprising producing reactive functional groups on the surface to provide an activated surface; and b) chemically bonding an inorganic adhesion layer to the functional groups of the activated surface; where the functional groups are reactive with an inorganic alkoxide to form the inorganic adhesion layer.
- the surface of the method can comprise a polymer, which can be selected from the group consisting of polyalkanes, polysiloxanes, polyalkylarenes, polyolefins, polythiols and polyphosphines.
- the surface functional groups of the method can be selected from the group consisting of hydroxyl, oxy, oxo, carbonyl, carboxylic acid, carboxylate, and amino groups.
- the activating step of the method can comprise chemical oxidation, using such chemical oxidizing agents as permanganate, chlorite, chromic acid, chromate, osmium tetroxide, ruthenium tetroxide, iodate, peracids, peroxides, Fenton’s reagent, lead tetraacetate, lead tetraacetate/Mn(II), ozone, of oxygen.
- the activating step of the method can comprise oxygen plasma discharge, nitrogen plasma discharge or corona discharge.
- Another aspect of the invention is directed to a method of activating and coating an unactivated surface with an inorganic oxide adhesion layer, comprising the steps of a) activating the surface of an unactivated substrate to the chemical bonding of an inorganic adhesion layer; b) providing a coating mixture comprising an organic solvent containing a reactive inorganic compound that is dissolved and/or dispersed in the solvent; and c) suspending the activated substrate in the coating mixture for a time and temperature sufficient to form an inorganic oxide coating on the activated surface, to provide a surface coated with an inorganic oxide adhesion layer; where the inorganic compound is selected from the group consisting of the alkoxides of Ti, Zr, Al, Mg, Si, Zn, Mo, Nb, Ta, Sn, W, and V.
- the method can further comprise d) removing the coated substrate from the coating solution; e) rinsing with a solvent to provide a rinsed coated substrate; and f) heating the rinsed coated substrate to 35 to 40°C.
- steps b) and c) can be replaced by vapor deposition of an inorganic alkoxide onto the surface, providing the inorganic oxide adhesion layer.
- Another aspect of the invention is directed to a construct having a SAMP, as disclosed above, where the R group is dodecyl-9-ynyl, further coupled at the alkyne using a metal- catalyzed reaction.
- the dodecyl-9-ynyl R group can also be further coupled at the alkyne using a click reaction.
- an aspect of the invention is directed to an adhesion layer-coated construct without a SAM or SAMP, further reacted directly at the inorganic adhesion layer with an organic moiety selected from the group consisting of electrochemically active moieties, photochemically active moieties, cell- attractive moieties, cell-adhesive moieties and anti-infective moieties.
- the anti- infective agent can comprise polysaccharides, chitosan, partially acetylated chitosan, polyglucosamine, chitosan diols, and other polyols (such as polyvinylalcohol) and aminoalcohols.
- the anti-infective moieties are selected from the group consisting of polysaccharides, chitosan, partially acetylated chitosan, polyglucosamine, chitosan diols, polyols, aminoalcohols and mixtures of two or more thereof.
- Proteins can also be directly attached to the inorganic adhesion layer. Suitable proteins include heparin and heparin derivatives such as heparin-functionalized phosphonate and silane pre-molecule (Heparin PUL and Heparin Silane, respectively).
- one aspect of the invention is directed to stainless steel (SS) coupons which were oxygen plasma-oxidized on both sides and dipped into a solution of titanium (IV) butoxide to form a Ti(IV) butoxide adhesion layer covalently attached to the SS surface.
- This coated SS surface was functionalized with heparin using either heparin-functionalized phosphonate or silane pre-molecule, and the heparin was found to be in its native form (vs. denatured) by XPS elemental analysis (see Example 5).
- One aspect of the invention is directed to a construct comprising: a) an activated surface comprising chemically accessible, reactive functional groups; and b) an inorganic alkoxide adhesion layer chemically bonded to the reactive functional groups of the activated surface; where the reactive functional groups are reactive with an inorganic alkoxide to form the inorganic adhesion layer, and the inorganic adhesion layer provides additional functional groups for further attachment of moieties that modify the overall surface properties.
- the activated surface of the construct can comprise an intrinsically unreactive surface towards chemical bonding of an inorganic adhesion layer, which has been treated to produce chemically accessible, reactive functional groups on the surface thereby providing activation.
- the surface of the construct can comprise a polymer, stainless steel, or a stainless steel alloy that is intrinsically unreactive towards chemical bonding of an inorganic adhesion layer.
- the polymer can be selected from the group consisting of polyalkanes, polysiloxanes, polyalkylarenes, polyolefins, polythiols and polyphosphines.
- the surface reactive functional groups can be selected from the group consisting of hydroxyl, oxy, oxo, carbonyl, carboxylic acid, carboxylate, and amino groups.
- the surface reactive functional groups can be produced by chemical oxidation.
- the chemical oxidation can comprise treatment with an oxidizing agent selected from the group consisting of permanganate, chlorite, chromic acid, chromate, osmium tetroxide, ruthenium tetroxide, iodate, peracids, peroxides, Fenton’s reagent, lead tetraacetate, lead tetraacetate/Mn(II), ozone, and oxygen.
- the surface reactive functional groups can be produced by oxygen plasma discharge, nitrogen plasma discharge, or corona discharge.
- the inorganic adhesion layer of the construct can comprise an inorganic oxide selected from the group consisting of the oxides of Ti, Zr, Al, Mg, Si, Zn, Mo, Nb, Ta, Sn, W, V, and mixtures of two or more thereof.
- the inorganic oxide adhesion layer is selected from the group consisting of the oxides of Al, Ti, Zr, Si, Mg, Zn, and mixtures of two or more thereof.
- the construct can further comprise a self-assembled monolayer (SAM) bonded to the additional functional groups of the inorganic adhesion layer, where the SAM is selected from organic compounds comprising a phosphonic, carboxylic, sulfonic, phosphinic, phosphoric, sulfinic, or hydroxamic group.
- SAM preferably comprises a self- assembled monolayer of phosphonates (SAMP).
- the phosphonates can be selected from the group consisting of hydrophobic phosphonates and cell-adhesive phosphonates.
- the hydrophobic and cell- adhesive phosphonates can be selected from the group consisting of phosphonic acids of structure
- R group is selected from the group consisting of optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted alkenyl, optionally substituted heteroalkenyl, optionally substituted alkynyl, optionally substituted heteroalkynyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, and optionally substituted hetero arylalkyl, where heteroalkyl, heteroalkenyl, heteroalkynyl, heteroaryl and hetero arylalkyl contain one or more heteroatoms selected from the group consisting of O, N and S.
- the R group of the construct can be dodecyl-9-ynyl, further coupled at the alkyne functional group using a metal-catalyzed reaction.
- the R group of the construct can be dodecyl-9-ynyl, further coupled at the alkyne functional group using a click reaction.
- the cell-adhesive phosphonates can be selected from the group consisting of C3-C30 a,w-diphosphonates.
- the SAM or SAMP of the construct can further comprise an anti- infective agent or an antithrombogenic agent covalently bound thereto.
- the anti-infective agent can be an antimicrobial selected from the group consisting of amikacin, gentamicin, kanamycin, neomycin, netilmicin, tobramycin, paromomycin, geldanamycin, herbimycin, loracarbef, ertapenem, doripenem, imipenem/cilastatin, meropenem, cefadroxil, cefazolin, cefalotin, cefalexin, cefaclor, cefamandole, cefoxitin, cefprozil, cefuroxime, cefditoren, cefoperazone, cefotaxime, cefpodoxime, ceftazidime, ceftibuten, ceftizoxime, ceftriaxone, cefepime, ceftaroline fo
- the anti- infective agent can be selected from the group consisting of polysaccharides, chitosan, partially acetylated chitosan, polyglucosamine, chitosan diols, polyols, aminoalcohols and mixtures of two or more thereof.
- the anti-infective agent can be selected from the group consisting of chlorhexidine, biguanides, cationic ammonium compounds, cationic ammonium dendrimers, silver, copper, cationic species and mixtures of two or more thereof.
- the cationic ammonium compounds can be selected from the group consisting of choline and choline derivatives.
- the antithrombogenic agent can be heparin.
- the construct of the invention can further comprise cells attached to the coated surface of the construct, where the cells are selected from the group consisting of fibroblasts, endothelial cells, keratinocytes, osteoblasts, chondroblasts, chondrocytes, hepatocytes, macrophages, cardiac muscle cells, smooth muscle cells, skeletal muscle cells, tendon cells, ligament cells, epithelial cells, stem cells, neural cells, PC12 cells, neural support cells, Schwann cells, radial glial cells, cells that form neurospheres, neural tumor cells, glioblastoma cells and neuroblastoma cells.
- the fibroblasts can comprise NIH 3T3 fibroblasts.
- the construct can further comprise an extracellular matrix (ECM).
- ECM extracellular matrix
- the construct can also be decelluarized to leave the ECM.
- construct as described above can have the inorganic adhesion layer directly attached to an organic moiety selected from the group consisting of
- electrochemically active moieties can be selected from the group consisting of
- polysaccharides chitosan, partially acetylated chitosan, polyglucosamine, chitosan diols, polyols, aminoalcohols and mixtures of two or more thereof.
- Another aspect of the invention is directed to a method of forming a construct as described above, the method comprising the steps of a) providing a surface that is intrinsically unreactive towards chemical bonding of an inorganic adhesion layer; b) activating the intrinsically unreactive surface to chemical bonding of an inorganic adhesion layer by treating the unreactive surface to produce reactive functional groups on the surface thereby providing an activated surface; and c) chemically bonding an inorganic adhesion layer to the reactive functional groups of the activated surface; where the reactive functional groups are reactive with an inorganic alkoxide to form the inorganic adhesion layer; and where the inorganic adhesion layer provides additional functional groups for further attachment of moieties that modify the overall surface properties.
- the surface can comprise a polymer that is intrinsically unreactive towards chemical bonding of an inorganic adhesion layer.
- the polymer can be selected from the group consisting of polyalkanes, polysiloxanes, polyalkylarenes, polyolefins, polythiols and polyphosphines.
- the surface functional groups generated by activation can be selected from the group consisting of hydroxyl, oxy, oxo, carbonyl, carboxylic acid, carboxylate, and amino groups.
- the activating step can comprise chemical oxidation.
- the chemical oxidation can comprise treatment with an oxidizing agent selected from the group consisting of permanganate, chlorite, chromic acid, chromate, osmium tetroxide, ruthenium tetroxide, iodate, peracids, peroxides, Fenton’s reagent, lead tetraacetate, lead tetraacetate/Mn(II), ozone, and oxygen.
- an oxidizing agent selected from the group consisting of permanganate, chlorite, chromic acid, chromate, osmium tetroxide, ruthenium tetroxide, iodate, peracids, peroxides, Fenton’s reagent, lead tetraacetate, lead tetraacetate/Mn(II), ozone, and oxygen.
- the activating step can comprise oxygen plasma discharge, nitrogen plasma discharge, or corona discharge.
- the inorganic adhesion layer of the method can comprise an inorganic oxide selected from the group consisting of the oxides of Ti, Zr, Al, Mg, Si, Zn, Mo, Nb, Ta, Sn, W, V, and mixtures of two or more thereof.
- the inorganic oxide adhesion layer is selected from the group consisting of the oxides of Al, Ti, Zr, Si, Mg, Zn, and mixtures of two or more thereof.
- Another aspect of the invention is directed to a method of activating an unactivated substrate surface and coating with an inorganic oxide adhesion layer, comprising the steps of: a) activating the surface of an unactivated substrate to chemical bonding of an inorganic adhesion layer by producing reactive functional groups on the surface to form an activated substrate; b) providing a coating mixture comprising an organic solvent containing a reactive inorganic compound that is dissolved and/or dispersed in the solvent; and c) suspending the activated substrate in the coating mixture for a time and at a temperature sufficient for the reactive functional groups and the inorganic compound to react and form an inorganic oxide coating on the activated surface of the substrate, providing a substrate coated with an inorganic oxide adhesion layer; where the inorganic compound is selected from the group consisting of the alkoxides of Ti, Zr, Al, Mg, Si, Zn, Mo, Nb, Ta, Sn, W, and V.
- the activating step of the method can comprise chemical oxidation.
- Chemical oxidation can comprise treatment with an oxidizing agent selected from the group consisting of permanganate, chlorite, chromic acid, chromate, osmium tetroxide, ruthenium tetroxide, iodate, peracids, peroxides, Fenton’s reagent, lead tetraacetate, lead tetraacetate/Mn(II), ozone, and oxygen.
- Steps b) and c) of the method can be replaced by vapor deposition of an inorganic alkoxide onto the surface of the activated substrate and reaction of the reactive functional groups with the inorganic alkoxide to form an inorganic oxide adhesion layer bonded thereto.
- the activating step can comprise oxygen plasma discharge, nitrogen plasma discharge or corona discharge.
- the method can further comprise: d) removing the coated substrate from the coating solution; e) rinsing with a solvent to provide a rinsed coated substrate; and f) heating the rinsed coated substrate to 35 to 40°C.
- the present method converts an otherwise unreactive material into one that is reactive at the surface.
- This surface reactivity can be controlled by the activation method and by nature of the coating layer of the activated surface, so that cell attachment, spreading and ECM formation are possible.
- Such means to direct the surface properties of materials provide many possible applications in medicine and other biomedical and biological fields.
- Solvents and chemical reagents include methanol (Sigma Aldrich), 2-propanol (Sigma Aldrich), tert-butanol (Fisher Scientific), 200 proof ethanol (Pharmco-Aaper), xylene (EMD Millipore Corporation), toluene (EMD Chemical Inc.), hexanes (Sigma Aldrich), titanium(IV) iso-propoxide (Sigma Aldrich), l,4-butanediphosphonic acid (Acros Organics), l,l2-dodecanediylbis(phosphonic acid) (Sigma Aldrich), and octadecylphosphonic acid (Alfa Aesar, Sigma Aldrich).
- Example 1 Oxygen Plasma-Oxidized PDMS having a titanium Ao-propoxide adhesion layer with an ODPA self-assembled monolayer
- Polydimethylsiloxane (PDMS) coupons were oxygen plasma-oxidized on one side and were dipped into a solution of titanium Ao-propoxide in toluene at a concentration of lOqL/mL. The samples were left submerged in the solution for 15 minutes. The coupons were removed from solution, and it was noted that the surfaces of these PDMS coupons had become slightly less translucent. The coupons were heated at 35 °C for 1 min, rinsed with ethanol, and then placed in a solution of octadecylphosphonic acid (ODPA) in toluene at a concentration of 0.5 mg/mL. The coupons were kept in this solution for several hours, removed from solution, heated at 35 °C for 1 min, and rinsed with ethanol.
- ODPA octadecylphosphonic acid
- Infrared Spectroscopy Infrared (IR) spectroscopy enables the detection of functional groups in a molecule by identifying unique peaks corresponding to the stretching and bending of chemical bonds. This same technique can be applied to SAMs on both optically transparent (transmission mode) and reflective (grazing angle spectral reflectance mode) substrates. IR can evaluate successful monolayer preparation and monitor degradation, as well as determine the degree of ordering in a SAM surface. Antisymmetric and symmetric methylene stretches are diagnostic peaks for alkyl-based monolayers, and appear in the vicinity of 2920 and 2850 cm -1 respectively.
- the wavenumbers for methylene group stretching modes are understood to be diagnostic of whether the chains exist in an all -trans configuration ("ordered” or crystalline state) or in a random configuration ("disordered” and "liquid-like” film).
- a well- ordered film in this work is defined to be characterized by antisymmetric methylene stretching wavenumber below 2920 cm -1 and symmetric methylene stretching wavenumber below 2850 cm -1 .
- ATR-FTIR data were taken using a Nicolet TMiSTM50 FT-IR Spectrometer.
- Example 2 A coupon of treated PDMS is prepared as described in Example 1 , and is treated with a solution of zirconium n-butoxide dissolved in toluene at a concentration of 0.5 mg/mL. The coupon is heated at 35 °C for 1 min, rinsed with ethanol, and is then placed in a solution of phosphonodec-9-yne in toluene at a concentration of 0.5 mg/mL. The coupon is kept in this solution for several hours, removed from solution, heated at 35 °C for 1 min, rinsed with ethanol, and analyzed by IR spectroscopy for the peaks that are characteristic of a terminal alkynyl group at ca. 2135 and 3325 cm -1 . A copper/palladium-catalyzed coupling reaction is then carried out with bromobenzene as an example to yield the 10-phenyl-coupled product.
- Example 3 A coupon of treated PDMS is prepared as described in Example 1 , and is treated with a solution of zirconium n-butoxide dissolved in toluene at a concentration of 0.5 mg/mL. The coupon is heated at 35 °C for 1 min, rinsed with ethanol, and is then placed in a solution of phosphonodec-9-yne in toluene at a concentration of 0.5 mg/mL. The coupon is kept in this solution for several hours, removed from solution, heated at 35 °C for 1 min, rinsed with ethanol, and analyzed by IR spectroscopy for the peaks that are characteristic of a terminal alkynyl group at ca. 2135 and 3325 cm -1 . A copper-catalyzed“click” reaction is then performed using phenyl azide to give the phenyltriazole-terminated phosphonate.
- Example 4 A coupon of treated PDMS is prepared as described in Example 1 , and is treated with a solution of zirconium n-butoxide dissolved in toluene at a concentration of 0.5 mg/mL. The coupon is heated at 35 °C for 1 min, rinsed with ethanol, and is then placed in a solution of glycerol in ethanol at a concentration of 0.5 mg/mL. The coupon is kept in this solution for several hours, removed from solution, heated at 35 °C for 1 min, rinsed with ethanol, and analyzed by IR spectroscopy for the peaks that are characteristic of hydroxyl, ether and aliphatic groups at around 1050, 2980 and 3100 cm -1 . Example 5.
- Solvents and chemical reagents include anhydrous toluene (Sigma Aldrich), tert-butanol (Fisher Scientific), 200 proof ethanol (Acros Organics), reagent alcohol (Fisher Scientific), titanium(IV) butoxide (Sigma Aldrich), monoamine functionalized trialkoxy silane and phosphonate (Gelest, Sikemia), Heparin sodium salt (Sigma Aldrich).
- Stainless Steel (SS) coupons were oxygen plasma-oxidized on both sides and were dipped into a solution of titanium (IV) butoxide in toluene at a concentration of 3% (v/v).
- the samples were left submerged in the solution for 15 minutes with constant stirring at 350 rpm.
- the Ti(IV) butoxide treated coupons were taken out of solution and allowed to dry inside a chemical hood for 5 minutes.
- the samples were then placed in an oven at 130°C for 10 min, then sonicated with reagent alcohol for 10 min (twice), and vacuum dried for 10 minutes.
- the coupons at this point had visible shades of gray on the surface when compared to control SS coupons.
- the samples were placed in a 1.5 - 15 mM ethanolic solution of heparin-functionalized phosphonate or silane pre-molecule (Heparin PUL or Heparin Silane) and were kept in this solution at a temperature ranging from 24 - 37°C overnight.
- Heparin PUL or Heparin Silane heparin-functionalized phosphonate or silane pre-molecule
- Heparin is a sugar dimer that repeats many times to make up a distribution of different molecular weights.
- the dimer is composed of five chemical elements. Four of those elements (carbon, oxygen, sulfur, and nitrogen) can be detected by XPS.
- the theoretical percent composition of these elements in heparin can be calculated and correlated with the experimentally observed elemental percent composition values as determined by XPS.
- X-ray Photon Spectroscopy is technique that measures the percent elemental composition of a surface-bound molecule by identifying the presence of specific elements within known functional groups in a molecule within a 10-nm depth profile. This same technique can be applied to surface-bound molecules to determine the presence of elements within functional regions, in addition to measuring deviations from native elemental percent composition values.
- XPS can evaluate successful surface preparation and monitor degradation of important domains in heparin due to different strategies used to bind heparin to stainless steel. Theoretically, the repeating dimeric unit in heparin has an elemental percent composition pattern of carbon (33%), oxygen (55%), sulfur (8.0%), and nitrogen (2.8%).
- the native elemental composition of heparin supports the interaction of heparin with anti-thrombin due to the key- lock interaction leading to structural changes on anti-thrombin and its activity to prevent thrombus formation.
- Significant changes in the elemental percent composition of sulfur are understood to be diagnostic of whether heparin is in its native or denatured form at the surface.
- the form of the covalently-bound heparin as prepared above was shown to be native by comparing its elemental percent composition versus the experimentally measured elemental percent composition values of native heparin; there were no statistically significant differences, thereby confirming the native covalently-bound form.
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762592880P | 2017-11-30 | 2017-11-30 | |
PCT/US2018/062958 WO2019108730A1 (en) | 2017-11-30 | 2018-11-29 | Adhesion layer bonded to an activated surface |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3718130A1 true EP3718130A1 (en) | 2020-10-07 |
EP3718130A4 EP3718130A4 (en) | 2021-01-20 |
Family
ID=66665787
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18883168.9A Pending EP3718130A4 (en) | 2017-11-30 | 2018-11-29 | Adhesion layer bonded to an activated surface |
Country Status (7)
Country | Link |
---|---|
US (1) | US20200360562A1 (en) |
EP (1) | EP3718130A4 (en) |
JP (1) | JP2021504096A (en) |
KR (1) | KR20200099152A (en) |
CN (1) | CN111937117A (en) |
AU (1) | AU2018374214A1 (en) |
WO (1) | WO2019108730A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3990195A4 (en) * | 2019-06-25 | 2023-10-04 | Molecular Surface Technologies, LLC | Electrochemical attachment of phosphonic acids to metallic substrates and antimicrobial medical devices containing same |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6645644B1 (en) * | 1996-10-17 | 2003-11-11 | The Trustees Of Princeton University | Enhanced bonding of phosphoric and phosphoric acids to oxidized substrates |
US5869141A (en) * | 1996-11-04 | 1999-02-09 | The Boeing Company | Surface pretreatment for sol coating of metals |
EP1828335B1 (en) * | 2005-01-21 | 2010-03-10 | Commonwealth Scientific And Industrial Research Organisation | Activation method using modifying agent |
US20070196663A1 (en) * | 2006-02-21 | 2007-08-23 | The Trustees Of Princeton University | High-yield activation of polymer surfaces for covalent attachment of molecules |
JPWO2008075714A1 (en) * | 2006-12-21 | 2010-04-15 | セイコーエプソン株式会社 | Thin film electronic device bonding substrate manufacturing method and electronic apparatus |
BRPI0720867A2 (en) * | 2006-12-29 | 2014-03-04 | 3M Innovative Properties Company. | METHOD FOR MANUFACTURING INORGANIC OR HYBRID / ORGANIC HYBRID MOVIES |
BRPI0721301A2 (en) * | 2006-12-29 | 2014-03-25 | 3M Innovative Properties Co | METHOD FOR HEALING FILMS CONTAINING METAL ALCOHIDE |
US8962097B1 (en) * | 2007-09-07 | 2015-02-24 | Edward Maxwell Yokley | Surface properties of polymeric materials with nanoscale functional coating |
CA2753423A1 (en) * | 2009-02-25 | 2010-09-02 | Orthobond Corp. | Anti- infective functionalized surfaces and methods of making same |
FR2944982B1 (en) * | 2009-04-30 | 2011-10-14 | Commissariat Energie Atomique | PROCESS FOR PREPARING A METALLIZED SUBSTRATE, ANDTHE SUBSTRATE AND USES THEREOF |
WO2013086149A1 (en) * | 2011-12-07 | 2013-06-13 | The Trustees Of Princeton University | Scaffolds for tissues and uses thereof |
US20170044710A1 (en) * | 2014-04-21 | 2017-02-16 | Dow Global Technologies Llc | Surface-treated fabricated article produced from polyolefin |
KR20170133321A (en) * | 2015-03-31 | 2017-12-05 | 도레이 카부시키가이샤 | Antithrombogenic metal material |
-
2018
- 2018-11-29 WO PCT/US2018/062958 patent/WO2019108730A1/en unknown
- 2018-11-29 JP JP2020548869A patent/JP2021504096A/en active Pending
- 2018-11-29 EP EP18883168.9A patent/EP3718130A4/en active Pending
- 2018-11-29 CN CN201880087749.0A patent/CN111937117A/en active Pending
- 2018-11-29 KR KR1020207018812A patent/KR20200099152A/en not_active Application Discontinuation
- 2018-11-29 US US16/768,009 patent/US20200360562A1/en active Pending
- 2018-11-29 AU AU2018374214A patent/AU2018374214A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20200360562A1 (en) | 2020-11-19 |
KR20200099152A (en) | 2020-08-21 |
CN111937117A (en) | 2020-11-13 |
AU2018374214A1 (en) | 2020-06-18 |
WO2019108730A1 (en) | 2019-06-06 |
JP2021504096A (en) | 2021-02-15 |
EP3718130A4 (en) | 2021-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sánchez-Bodón et al. | Bioactive coatings on titanium: a review on hydroxylation, self-assembled monolayers (sams) and surface modification strategies | |
Adden et al. | Phosphonic acid monolayers for binding of bioactive molecules to titanium surfaces | |
RU2501572C2 (en) | Anti-infectious functionalised surfaces and methods for preparing them | |
Mani et al. | Stability of self-assembled monolayers on titanium and gold | |
Gadenne et al. | Antiadhesive activity of ulvan polysaccharides covalently immobilized onto titanium surface | |
Bertazzo et al. | Control of α-alumina surface charge with carboxylic acids | |
Geuli et al. | Composition-tailoring of ZnO-hydroxyapatite nanocomposite as bioactive and antibacterial coating | |
Danahy et al. | Self-assembled monolayers of α, ω-diphosphonic acids on Ti enable complete or spatially controlled surface derivatization | |
Canepa et al. | Anchoring of aminophosphonates on titanium oxide for biomolecular coupling | |
EP2919920B1 (en) | Method for grafting polymers on metallic substrates | |
Flade et al. | Osteocalcin-controlled dissolution− reprecipitation of calcium phosphate under biomimetic conditions | |
EP3782661B1 (en) | Polydopamine film and preparation method and use thereof | |
US20200360562A1 (en) | Adhesion layer bonded to an activated surface | |
Li et al. | Biofunctionalization of a “Clickable” organic layer photochemically grafted on titanium substrates | |
Muzzarelli et al. | Chitosan-oxychitin coatings for prosthetic materials | |
La Zara et al. | Sub-nanoscale surface engineering of TiO2 nanoparticles by molecular layer deposition of poly (ethylene terephthalate) for suppressing photoactivity and enhancing dispersibility | |
Guo et al. | Robust antibacterial activity of xanthan-gum-stabilized and patterned CeO2–x–TiO2 antifog films | |
Li et al. | Photochemical grafting and patterning of biomolecular layers onto TiO2 thin films | |
CN101347634B (en) | Method for processing surface functionalization and modification of biological medical titanium alloy | |
US20210128791A1 (en) | Galvanic redox material and implantable device and methods thereof | |
Azizova et al. | Parameters controlling octadecyl phosphonic acid self-assembled monolayers on titanium dioxide for anti-fouling biomedical applications | |
US9655992B2 (en) | Surface modified biological materials | |
Zorn et al. | Contact-Biocide TiO2 Surfaces by Surface-Initiated Atom Transfer Radical Polymerization with Chemically Stable Phosphonate Initiators | |
Acharya et al. | A general method for fabrication of biocompatible surfaces by modification with titania layer | |
JP4570445B2 (en) | Method for producing an indwelling medical device having a hybrid complex on its surface |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20200629 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20201217 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: H01L 21/00 20060101AFI20201211BHEP Ipc: H01L 21/30 20060101ALI20201211BHEP |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20220928 |